ProKidney Corp (NASDAQ: PROK) Not A Good Play Anymore?

ProKidney Corp (PROK) concluded trading on Thursday at a closing price of $1.64, with 0.47 million shares of worth about $0.76 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.04% during that period and on March 28, 2024 the price saw a gain of about 4.46%. Currently the company’s common shares owned by public are about 59.88M shares, out of which, 48.73M shares are available for trading.

Stock saw a price change of 19.71% in past 5 days and over the past one month there was a price change of 4.46%. Year-to-date (YTD), PROK shares are showing a performance of -7.87% which decreased to -86.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.12 but also hit the highest price of $13.51 during that period. The average intraday trading volume for ProKidney Corp shares is 579.61K. The stock is currently trading 7.07% above its 20-day simple moving average (SMA20), while that difference is up 13.13% for SMA50 and it goes to -66.41% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


ProKidney Corp (NASDAQ: PROK) currently have 59.88M outstanding shares and institutions hold larger chunk of about 52.62% of that.

The stock has a current market capitalization of $110.11M and its 3Y-monthly beta is at 1.28. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 14.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PROK, volatility over the week remained 7.45% while standing at 9.50% over the month.

Analysts are in expectations that ProKidney Corp (PROK) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.59 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.16 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -67.37% while it is estimated to increase by 54.57% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on March 07, 2024 offering an Equal-weight rating for the stock and assigned a target price of $3 to it. On July 25, 2023, BTIG Research Initiated their recommendations, while on December 21, 2022, Jefferies Initiated their ratings for the stock with a price target of $15. Stock get an Equal-weight rating from Morgan Stanley on November 10, 2022.

Most Popular

Related Posts